Company profile: IntraOp
1.1 - Company Overview
Company description
- Provider of compact, mobile electron therapy devices and platforms for cancer treatment, including Mobetron, a self-shielded electron-beam linear accelerator for intraoperative radiation therapy; FLASH-IQ, delivering UHDR electron beams for preclinical and investigational FLASH radiotherapy; and non-invasive electron therapy for non-melanoma skin cancer.
Products and services
- Electron Therapy for Skin Cancer: A point-of-care, non-invasive electron therapy for non-melanoma skin cancer, delivering precise radiation with minimal recovery time and expanding access to effective treatment for patients
- FLASH-IQ: A UHDR-capable radiotherapy platform that delivers ultra-high dose rate electron beams for preclinical and investigational studies of FLASH radiotherapy
- Mobetron: A self-shielded electron-beam linear accelerator enabling oncologists to deliver precise intraoperative radiation therapy (IORT) during surgery to cancer patients with effective electron therapy
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to IntraOp
SciBase
HQ: Sweden
Website
- Description: Provider of medical devices leveraging Electrical Impedance Spectroscopy (EIS) to detect malignant melanoma and assess skin barrier function. Products include Nevisense, a point-of-care platform using EIS and AI for non-invasive melanoma detection and objective clinical decision-making, and Nevisense Go, a portable EIS device for detailed skin barrier assessment in research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SciBase company profile →
Terremoto Bio
HQ: United States
Website
- Description: Provider of a lysine-targeted covalency drug discovery and development platform to create optimized small-molecule medicines against a wide range of protein targets, including those previously considered undruggable. Offerings include structure-based drug design, screening platform development, cryo-EM, X-ray crystallography, and a computational discovery engine to accelerate new medicine creation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Terremoto Bio company profile →
Mevion Medical Systems
HQ: United States
Website
- Description: Provider of innovative, safe, and effective radiation therapy solutions for the treatment of cancer, pioneering modern proton therapy systems and transforming advances in medical technology and science into practical clinical solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mevion Medical Systems company profile →
MAIA Biotechnology
HQ: United States
Website
- Description: Provider of immuno-oncology drug R&D, developing first-in-class therapies with novel mechanisms, including THIO, an investigational telomere-targeting candidate that induces immune responses in cancer cells (Phase 2 in non-small cell lung cancer), and second-generation telomere-targeting agents in early discovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MAIA Biotechnology company profile →
Deciphera Pharmaceuticals
HQ: United States
Website
- Description: Provider of kinase inhibitor–based cancer medicines leveraging a proprietary switch-control platform. Commercializes Ripretinib (QINLOCK) for advanced gastrointestinal stromal tumor after treatment with three or more kinase inhibitors, and develops a pipeline including Vimseltinib (CSF1R) for TGCT, DCC-3116 (ULK1/2) for cancers with RAS/RAF mutations, DCC-3084 (pan-RAF), and DCC-3009 (next‑gen KIT).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Deciphera Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for IntraOp
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to IntraOp
2.2 - Growth funds investing in similar companies to IntraOp
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for IntraOp
4.2 - Public trading comparable groups for IntraOp
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →